(Solid Tumors) Is Keytruda (Pembrolizumab) Effective as Neoadjuvant Therapy?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- February 3, 2023
- Reading time: 1 minute
On January 9, 2023, Kaysia Ludford and colleagues from The University of Texas MD Anderson Cancer Center published Phase 2 clinical trial (NCT04082572) results in the Journal of Clinical Oncology, evaluating the efficacy and safety of Keytruda (pembrolizumab) as neoadjuvant therapy in patients with advanced metastatic solid tumors with MSI-High and dMMR status.
Trial Design
This was an open-label, independent-facility Phase 2 trial administering Keytruda (600 mg every 3 weeks, maximum 6 months) as neoadjuvant therapy to patients with advanced metastatic MSI-High/dMMR solid tumors. Following surgery, patients could continue treatment for up to one year based on individual choice. Primary endpoints: pathologic complete response (pCR) rate and safety. Secondary endpoint: organ preservation rate in patients not undergoing surgery.
Efficacy Results
Among 35 enrolled patients (27 colorectal cancer, 8 non-colorectal cancer):
- ORR (33 evaluable patients): 82%
- Pathologic complete response rate (17 surgical patients): 65%
Safety Profile
No new adverse events were identified; safety profile was consistent with known Keytruda data from other clinical trials.
Conclusions
Based on Phase 2 results, Kaysia Ludford et al. concluded that neoadjuvant Keytruda in MSI-High/dMMR advanced metastatic solid tumor patients demonstrated good tolerability and favorable pathologic complete response rates, offering patients an organ-preservation option.
Source: https://ascopubs.org/doi/abs/10.1200/JCO.22.01351?journalCode=jco
- Clinical trial drug
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4